Phase IIb data of Metsera Inc.’s lead GLP-1 receptor agonist, MET-097i, showed significant weight loss and good tolerability, supporting a phase III start later this year, and validating Pfizer Inc.’s ...

Tesla Inc.’s chair insists no one other than Elon Musk is capable of leading the company’s transition into artificial intelligence and robotics — but it’s possible he won’t do it from the CEO’s seat. ...

When Jerry Vagnier interviewed for executive director of Special Growers, he didn’t meet up with their leadership in a corner downtown office. Instead, he headed out to the farm property just off ...

Former FieldWare CEO brings deep integration and revenue expertise to accelerate global execution. Athos Commerce today announced the appointment of Chuck Haling as Chief Executive Officer. A ...

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema Phase IIb trial to ...

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Wednesday announced progress in the design and planning of its upcoming Phase 3 trial evaluating AD04, the company's lead investigational genetically ...

Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the ...

The Centers for Disease Control and Prevention has rejected a request from health officials in Milwaukee for help with a lead poisoning investigation, after Health and Human Services Secretary Robert ...

The Centers for Disease Control and Prevention's team of lead poisoning experts remained off the job Tuesday, a week after they were first laid off by Health and Human Services Secretary Robert F.